Compound Characterization: The Analytical Foundation
No peptide research protocol is methodologically defensible without prior chemical characterization of the compound under study. The minimum characterization package for a research-grade peptide consists of: (1) identity confirmation by electrospray ionization mass spectrometry (ESI-MS) — the observed monoisotopic [M+H]⁺ or multiply charged [M+nH]ⁿ⁺ ions must match the theoretical mass within ≤5 ppm on an Orbitrap or Q-TOF instrument; (2) sequence confirmation by tandem MS/MS fragmentation analysis — b-ion and y-ion series must confirm the amino acid sequence without ambiguity; (3) purity determination by HPLC-UV — C18 reverse-phase column, 0.1% TFA in water/acetonitrile gradient, UV detection at 220 nm (peptide bond absorbance), with purity calculated as (main peak area / total integrated chromatogram area) × 100%, where ≥95% is the minimum threshold for biological assay use; (4) endotoxin content by Limulus Amebocyte Lysate (LAL) test — ≤1 EU/mg for cell-based assays, ≤0.1 EU/mg for in vivo use in rodents; (5) water content by Karl Fischer coulometric titration — critical for accurate mass-based dosing, as lyophilized peptides routinely contain 5-15% water. A Certificate of Analysis (CoA) reporting all five parameters, issued by the supplying laboratory and available for every lot number, is the minimum documentation standard for publication-quality peptide research.
Lot Traceability and Source Documentation
Reproducibility in peptide research requires that the exact compound used in a study can be traced to a specific manufacturing lot with associated analytical data. Lot numbers should follow a structured format encoding supplier identity, synthesis year, quarter, peptide identifier, and sequential batch number — enabling cross-study comparison and retrospective identification of quality-related confounding factors. When a study reports effects that differ from earlier work with the same peptide, the first questions to ask are: (1) were the same lot numbers used, (2) were the CoA parameters comparable, (3) was the purity ≥95% in all cases? Counterion specification is frequently overlooked but is analytically and pharmacologically relevant: TFA (trifluoroacetic acid) counterion, the default from HPLC purification, is cytotoxic to most cell lines at concentrations exceeding 0.5 mM. For cell-based assays, TFA counterion must be replaced by ion exchange to acetate or chloride; failure to document counterion species is a methodological deficiency that has confounded multiple published peptide cell biology studies. Researchers must request counterion specification on the CoA and report it in the methods section of publications.
Protocol Pre-Registration and Study Reporting Standards
Research protocols for peptide experiments — whether in vitro, ex vivo, or in vivo — should be pre-registered before data collection begins. For in vivo rodent studies, appropriate pre-registration platforms include the Open Science Framework (OSF) and the preclinical trial registry maintained by the NC3Rs. Pre-registration serves two functions: it prevents outcome switching (changing the primary endpoint after seeing results) and it provides an auditable record of the original hypothesis being tested. The ARRIVE 2.0 guidelines (Animal Research: Reporting of In Vivo Experiments, 2020) define the minimum information required in publications reporting in vivo peptide experiments: species, strain, sex, age, housing conditions, randomization method, blinding status, primary endpoint, statistical method with power calculation justification, and full reporting of all pre-specified outcome measures including null results. Adherence to ARRIVE 2.0 is now a submission requirement at most high-impact journals publishing animal experimental data.
Statistical Power, Sample Size Justification, and Data Integrity
Sample size calculations for peptide experiments must be based on: (1) the minimum clinically or biologically relevant effect size (not the maximum observed effect in pilot data, which is subject to winner's curse inflation), (2) the expected variance in the primary endpoint under control conditions (derived from historical data or pilot experiments with adequate baseline characterization), (3) the desired statistical power (conventionally ≥80%, preferably 90% for confirmatory experiments), and (4) the significance threshold with appropriate correction for multiple comparisons. For dose-response studies, the minimum number of dose points for fitting a sigmoid Emax model is four (EC20, EC50, EC80, Emax) with ≥6 replicate observations per dose point to adequately characterize the Hill coefficient. Data integrity in peptide research is protected by pre-analysis data archiving (raw instrument output files, not processed spreadsheets), timestamped electronic lab notebooks, and blinded analysis — where the analyst processing data is unaware of group assignments until after statistical analysis is complete. The FDA's 21 CFR Part 11 and the European Commission's Annex 11 to EudraLex define electronic data integrity requirements; these apply to GLP-compliant preclinical studies and should be adopted as standards for non-GLP research as well.
Quality Management in Peptide Research: From Storage to Assay
Peptide stability during storage is a systematic source of experimental variability that is frequently underappreciated. Lyophilized peptides should be stored at -20°C or -80°C with desiccant, protected from light, and not subjected to repeated freeze-thaw cycles. The number of freeze-thaw cycles a working stock has undergone should be recorded and reported; for most peptides, purity begins to degrade measurably after three to five freeze-thaw cycles. Reconstitution vehicles must be specified: sterile water, 0.9% NaCl, and DMSO (≤0.1% v/v for cell-based assays) have different implications for peptide stability and assay interference. Vehicle controls must always be included at equivalent dilutions to reconstitution vehicles used for the peptide. Reference standard calibration — using a freshly characterized reference lot to verify instrument performance before each analytical run — is required for GLP-compliant work and is best practice for non-GLP research. Documenting and reporting all quality management steps is not administrative overhead; it is the methodological substrate on which biological interpretation depends.
These compounds are for research and laboratory use only. Not for unsupervised human consumption.